Navigation Links
Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Jun 4, 2007 - Cougar Biotechnology, Inc. (OTCBB: CGRB) today announced that positive interim Phase I and Phase II data on the Company's prostate cancer drug candidate CB7630 (abiraterone acetate) was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is currently taking place in Chicago, Illinois. The data was presented in two poster presentations on Saturday, June 2nd, as part of the poster discussion session for genitourinary (prostate) cancer that took place. The poster presentations are further detailed below:

Phase I/II Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone, in Castration-Resistant Prostate Cancer Patients Incorporating the Evaluation of Androgens and Steroid Metabolites in Plasma and Tumor and the Study of Circulating Tumor Cells

The Phase I/II trial of CB7630 was conducted at The Institute of Cancer Research and at The Royal Marsden NHS Foundation Trust in the United Kingdom. In the trial, CB7630 was administered orally, once daily, to chemotherapy-naive patients with castration resistant prostate cancer (CRPC), who had progressive disease despite treatment with LHRH analogues and multiple other hormonal therapies, including antiandrogens, diethylstilboestrol and dexamethasone. To date, a total of 42 patients have been treated in the Phase I/II trial, including 15 patients treated in the Phase I stage of the trial and 27 patients treated in the Phase II stage of the trial. In his poster presentation, Dr. Gerhardt Attard from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in the United Kingdom reported that in the 42 patients treated in this trial, CB7630 was well tolerated at doses as high as 2000 mg/day with minimal toxicity. Moreover, no dose limiting toxicity has been observed in the trial to date.

In the 34 patients who were evaluable for response in the
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:7/11/2014)... Fla. , July 11, 2014  Rock Creek ... biotechnology company, today announced that the Food and Drug ... will provide comments on RCP,s Investigational New Drug ("IND") ... clinical trial in the US. Dr. ... agency,s review and comments on our IND. When we ...
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... SCHAUMBURG, Ill. , Jan. 19 ... pharmaceutical company, today announced that it has launched ... per 10 mL and 90 mg per 10 mL.  Pamidronate disodium ... Aredia®, is a bone resorption inhibitor.  The 2008 ...
... , FRANKLIN LAKES, N.J. , Jan. ... MHS ) are scheduled to present at the following investor conferences: , ... the Jeffries 2010 Global Healthcare Services Conference on Monday, January 25, ... hotel in New York ; , David B. Snow Jr. ...
Cached Medicine Technology:Sagent Pharmaceuticals Launches Pamidronate Disodium Injection 2Medco to Present at Upcoming Investor Conferences 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 The Passenger ... million in 2013 to $20,341.36 million by 2019, at ... 2013 and 2019. , The public transport infrastructure in ... is also available in almost every corner of the ... the interest of public transport service providers are driving ...
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives (Plasticizers, ... & Geography – Trends & Forecast to 2018," defines ... of market volume and value. The report also estimates ... market of phthalic anhydride is projected to grow from ... by 2018, with a CAGR of 5.24% from 2013 ...
(Date:7/12/2014)... 12, 2014 In this ... ‘cognitive assessment and training’ is defined as ... train, or enhance cognitive functions. These solutions ... in dementia screening, clinical trials, driver’s safety, ... self assessment, brain training, and employers’ assessment ...
(Date:7/12/2014)... 12, 2014 The fastest-growing mobile technology ... and measurement of LTE networks continues to grow due ... smart devices have increased mobile data traffic, which is ... (CT&M) market. Communications Test and Measurement equipment comply with ... The Communications Test and Measurement Market is estimated to ...
(Date:7/12/2014)... make exercise fun, you,ll eat less after your workout, new ... on a 1.4-mile walk and were either told it would ... were given lunch after the walk, and those who were ... chocolate pudding for dessert than those who were told it ... were given mid-afternoon snacks after their walk. Those who were ...
Breaking Medicine News(10 mins):Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2
... by the British Heart Foundation says that British Asians are ... to heart disease than people// of European origin. One in ... 3 percent of the general population in the UK. ... diabetes, abnormal cholesterol levels and high blood pressure amongst South ...
... Journal of Respiratory and Critical Care Medicine says that ... the blood could// help detect abnormal lesions like cancer ... of inflammation and measuring the blood levels of this ... developing lesions that could cause irreversible damage. ...
... components such as polyphenols. This is essential in preventing periodontal ... found to affect the gums and the bone that surrounds ... factor in preventing it. ,If not prevented ... Statistics show that about 15 % of those aged 21 ...
... come to an end after the health authorities promised to pay ... and working hours//. ,As word spread that the doctors ... Long queues were seen in the city's hospitals. ,'It ... son's eye surgery was fixed for Sunday and we were wondering ...
... An overseas-trained doctor, Farid Zaer, who has registered himself ... to Queensland, to continue his medical practice.// The doctor ... been accused for wrong diagnosis involving nearly 208 patients. ... work as a GP, without any restriction or supervision. ...
... of the oral cavity can be effectively treated by ... at Buffalo's School of Dental Medicine. ,Photodynamic ... currently employed in the treatment of Kaposi's sarcoma, breast ... the esophagus. ,The treatment modality involves administration ...
Cached Medicine News:Health News:Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered 2Health News:Infections Of The Oral Cavity Can Be Treated By Photodynamic Therapy 2
...
... The QuickLink™ Delivery System ... device designed to assemble ... SourceLink Connectors into seed ... and with variable seed ...
Stylish yet conservative, these classics are reliable, comfortable and durable....
Inquire...
Medicine Products: